Subway has been placed in a difficult situation after The New York Times released its lab test report on the sandwich chain’s Subway tuna product. It was said that the publication initiated the lab test due to the company’s lawsuits.
As per Fox Business, a 60-inch Subway tuna sandwich was tested at a lab and the result stated that “no amplifiable tuna DNA was present” in the food item. This means that the lab analysis failed to find or identify any tuna DNA in the food.
The tuna sandwich test
Subway has been wrapped up in some lawsuits regarding its sandwiches. Customers have different complaints but there was a customer who said that the tuna in the tuna sandwich is not the fish that everyone knows. In simpler words, it was claimed that the tuna could not be real tuna meat.
In any case, in The New York Times report, it said that it brought sandwiches from three different Subway outlets around Los Angeles for testing. This was done after a customer filed a lawsuit earlier this year, claiming the tuna fish is made from "a mixture of various concoctions."
For the lab test, the tuna was frozen and was brought to the lab. It was mentioned that a PCR test was done to determine if the tuna from Subway’s sandwiches is one of the five tuna species. However, the lab could not identify which species because it did not find tuna DNA at all.
It is fake tuna?
Then again, it cannot be assumed that Subway is using fake tuna in its sandwiches. In fact, this may not be the truth because it was explained that there are two possible reasons why the tuna DNA was not detected.
"One, it’s so heavily processed that whatever we could pull out, we couldn’t make an identification,” the lab’s spokesman told The New York Times. “Or we got some and there’s just nothing there that’s tuna."
On the other hand, some experts said that it is also possible that the DNA disappeared when tuna was cooked. Because in this process, the protein breaks down and this makes it difficult to spot the DNA.


Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 



